Issue with Evaluating Costs Over Time in a Context of Medical Guideline Changes: An Example in Myocardial Infarction Care Based on a Longitudinal Study from 1997 to 2018

Clinicoecon Outcomes Res. 2022 Jan 7:14:11-20. doi: 10.2147/CEOR.S340385. eCollection 2022.

Abstract

Background: Cost studies appear sporadically in the scientific literature and are rarely revised unless drastic technological advancements occur. However, health technologies and medical guidelines evolve over time. It is unclear if these changes render obsolete prior estimates. We examined this issue in a cost study in the context of patients' first myocardial infarction (MI), a clinical area prone to such continuous evolution in care.

Methods: We conducted a longitudinal cost analysis based on a Quebec cohort. Quebec health administrative databases were used to identify incident MI cases using diagnostic codes from the international classification of diseases (ICD-9 and ICD-10). Physician fees and hospitalization costs (ie, costs incurred by the hospital center) were derived from administrative databases and a university hospital's finance department. All costs were converted to 2019 Canadian dollars. Nonparametric bootstraps were used to estimate 95% confidence intervals (CI) of the average costs of an episode of care. Generalized linear regressions were used to examine temporal trends of cost.

Results: Our study sample consists of 261 patients hospitalized for a first MI. The average total cost for this first event was estimated at $5782 (95% CI: $5293 - $6373). Though total costs remained stable over time, physician fees increased by 123% ($1240 vs $2761) whereas total hospital length of stay dropped by 17% (6.6 vs 5.5 days) over the 21-year period.

Conclusion: Patients' first MI hospitalization impose an economic burden on the healthcare system. Though overall costs remained stable, our results suggest that some cost components varied over time.

Keywords: cost study; longitudinal study; methods; myocardial infarction; observational data.

Grants and funding

Work presented in this manuscript was funded by the Réseau québécois de recherche sur les medicaments (RQRM), a thematic network supported by the Fonds de recherche du Québec–Santé; the funding agreements ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. MGO holds the Chaire de recherche du Canada sur le sexe et le genre en santé au travail. JRG is the recipient of a Chercheur-boursier Junior 1 career award from the Fonds de recherche du Québec-Santé (FRQS #266460).